In a patient with acute myocardial infarction who is allergic to aspirin, what dual antiplatelet therapy should be administered?

Dual Antiplatelet Therapy in Aspirin-Allergic AMI Patients

In patients with acute myocardial infarction who are allergic to aspirin, use clopidogrel 75 mg daily OR ticagrelor 90 mg twice daily as monotherapy indefinitely, with aspirin desensitization as an alternative strategy if feasible. 1, 2, 3

Primary Recommendation

The most direct guideline-based approach for aspirin-allergic AMI patients is P2Y12 inhibitor monotherapy:

• Clopidogrel 75 mg daily (Level of Evidence: B) 1, 2
• Ticagrelor 90 mg twice daily (Level of Evidence: C) 2, 3
• Prasugrel 10 mg daily (in PCI-treated patients only) (Level of Evidence: C) 2, 3

These recommendations come from the 2012 ACCF/AHA guidelines which explicitly state that when aspirin is contraindicated due to hypersensitivity, a P2Y12 receptor inhibitor should be given as monotherapy 2, 3.

Critical Caveat: No Dual P2Y12 Inhibitor Therapy

There are NO data supporting the use of two concurrent P2Y12 receptor inhibitors, and this is explicitly NOT recommended 2, 3. This is a common pitfall—do not attempt to create "dual antiplatelet therapy" by combining clopidogrel with ticagrelor or prasugrel.

Aspirin Desensitization as Alternative Strategy

For patients requiring true dual antiplatelet therapy (especially post-PCI with stent placement), aspirin desensitization should be strongly considered 2, 4, 5:

• Allows for standard DAPT (aspirin + P2Y12 inhibitor)
• More cost-effective than long-term alternative strategies 5
• Particularly valuable in high-risk patients requiring optimal antiplatelet coverage
• Recent case reports demonstrate successful implementation in AMI settings 4, 5

Specific Clinical Scenarios

Post-PCI with Stent Placement

If the patient undergoes PCI with stent implantation:

1. First-line: Attempt aspirin desensitization to enable standard DAPT 2, 4, 5
2. If desensitization fails or unavailable:
   • Use ticagrelor 90 mg twice daily as monotherapy (preferred over clopidogrel for superior efficacy) 6, 7
   • Continue for at least 12 months 2, 3, 7
   • Consider cilostazol as alternative (though less evidence) 8

Conservative (Non-PCI) Management

For medically managed AMI without revascularization:

• Clopidogrel 75 mg daily OR ticagrelor 90 mg twice daily as monotherapy 2, 3
• Continue indefinitely 1, 9

Drug Selection Hierarchy

Ticagrelor is preferred over clopidogrel when available, based on the 2025 ACC/AHA guidelines showing superior outcomes in ACS 6. However, both are acceptable alternatives to aspirin 2, 3.

Prasugrel should NOT be used if the patient has:

• History of stroke or TIA (absolute contraindication) 2, 7
• Age ≥75 years (generally not recommended) 2, 3
• Body weight <60 kg (increased bleeding risk) 2, 3

Practical Algorithm

1. Confirm true aspirin allergy (hypersensitivity vs. intolerance)
2. If PCI planned: Consult allergy/immunology for rapid aspirin desensitization protocol 4, 5
3. If desensitization successful: Proceed with standard DAPT (aspirin + P2Y12 inhibitor)
4. If desensitization fails/unavailable:
   • Start ticagrelor 90 mg BID (preferred) OR clopidogrel 75 mg daily
   • Continue as monotherapy for ≥12 months
   • Do NOT combine two P2Y12 inhibitors
5. Add gastroprotection with proton pump inhibitor to reduce GI bleeding risk 6

Important Monitoring

• Bleeding risk assessment is critical with any antiplatelet strategy 2, 3
• If high bleeding risk develops, consider shortening duration to 6 months (though data limited) 2, 7
• Patient compliance is especially important with ticagrelor (twice-daily dosing) 2